VKTX
Viking Therapeutics (VKTX) Stock Valuation
Review Viking Therapeutics (VKTX) valuation with company data, supporting context and links to related investor research.
Research record updated: . Individual measures may refer to different reporting periods.
- Price to book
- 6.22
- BTI fair market cap
- $471.61M
- Premium or discount
- 601.85%
- Market cap
- $3.31B
Viking Therapeutics (VKTX) Stock Valuation research
The Viking Therapeutics valuation page presents the available multiples, profitability measures and BTI fair-value context for VKTX. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.
BTI fair value is a model estimate, not a quoted market price. The underlying assumptions and valuation date must be checked in the valuation tool before using the premium or discount. A missing multiple must not be interpreted as zero cost or zero risk.